Trump administration ends Medicaid loophole in drug rebates

Published



Drug companies will be unable to game a requirement to give states large prescription rebates through Medicaid under a law the Trump administration implemented Thursday.

The guidance closes a loophole that drug companies exploited by making superficial changes to existing drugs to inflate their costs and thus pay states less than they owed. The changes allowed drug companies to treat the medicines as new drugs and change the rebate calculation.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.